Atyr Pharma Inc (ATYR)

$0.79 -0.01 (-0.83%)
Market Cap 77.63M
Revenue (ttm) 190,000.00
Net Income (ttm) -74.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -39,010.53%
Debt to Equity Ratio 0.00
Volume 908,300
Avg Vol 1,149,958
Day's Range N/A - N/A
Shares Out 98.05M
Stochastic %K 5%
Beta 0.64
Analysts Sell
Price Target $4.50

Company Profile

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 731 8389
Fax: 858 731 8394
Address:
10240 Sorrento Valley Road, Suite 300, San Diego, United States
trader2sde
trader2sde Apr. 25 at 10:19 AM
$ATYR reminder.... imho no coincidence and it is about time. he is a trouble maker! . Dr. Vinay Prasad, the FDA's controversial head of vaccine and biotech evaluation (CBER), will leave his post at the end of April 2026, marking his second departure from the role in less than a year. His tenure was marked by friction with the biotech industry and intense scrutiny over regulatory decisions regarding drug approvals. Key Details on the Departure: Second Departure: Prasad previously resigned in July 2025, returning only two weeks later before this final, planned exit. Controversial Tenure: He was known for pushing stricter review standards and challenging industry practices, such as questioning gene therapies and delaying certain approvals. Industry Clashes: His recent actions involved disputes with companies like UniQure (over Huntington's disease trials) and Moderna (regarding an mRNA flu vaccine).
0 · Reply
jamersonmoody
jamersonmoody Apr. 24 at 7:32 PM
$ATYR lol fuck this pos
0 · Reply
Bocholter
Bocholter Apr. 24 at 7:02 PM
$ATYR lovely shorties…..think about it🔥🔥🔥🤑🤑🤑😊😊😊
0 · Reply
Spiceman63
Spiceman63 Apr. 24 at 6:02 PM
$ATYR It should be any day… “We look forward to meeting with the FDA in mid-April to review the results of our Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr Pharma. “We expect to provide an update regarding the outcome of the meeting following the receipt of the official meeting minutes.”
2 · Reply
Bocholter
Bocholter Apr. 24 at 4:18 PM
$ATYR buy buy buy guys🤑🔥🔥🔥
0 · Reply
Bocholter
Bocholter Apr. 24 at 3:01 PM
$ATYR The short sellers are about to break a sweat. The good news… we’re finally heading north again. Keep an eye on the chart today 🔥🔥🔥🤑🤑🤑
0 · Reply
trader2sde
trader2sde Apr. 24 at 10:42 AM
$ATYR
0 · Reply
trader2sde
trader2sde Apr. 24 at 10:42 AM
$ATYR
0 · Reply
ClearCities
ClearCities Apr. 23 at 9:38 PM
$ATYR all the focus is on meeting for type c i expect a 2sp +and stabilize
1 · Reply
Houzehero
Houzehero Apr. 23 at 8:54 PM
$ATYR Forget today's noise, FDA minutes are due to drop by Mid-May and call options are leaning toward ⬆️
1 · Reply
Latest News on ATYR
Ethos Collaborates with Liberty Mutual to Deliver a Modern, Digital-First Life Insurance Experience

Apr 23, 2026, 9:07 AM EDT - 1 day ago

Ethos Collaborates with Liberty Mutual to Deliver a Modern, Digital-First Life Insurance Experience

LIFE

Ethos to Announce First Quarter 2026 Financial Results on May 6, 2026

Apr 2, 2026, 4:05 PM EDT - 22 days ago

Ethos to Announce First Quarter 2026 Financial Results on May 6, 2026

LIFE

Ethos and Banner Life Expand Offering to Bring Final Expense Coverage to More Families

Mar 24, 2026, 4:05 PM EDT - 4 weeks ago

Ethos and Banner Life Expand Offering to Bring Final Expense Coverage to More Families

LIFE

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

Mar 5, 2026, 4:01 PM EST - 7 weeks ago

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

Ethos to Participate in The Citizens Technology Conference

Feb 26, 2026, 4:06 PM EST - 2 months ago

Ethos to Participate in The Citizens Technology Conference

LIFE

Ethos Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Feb 25, 2026, 4:05 PM EST - 2 months ago

Ethos Reports Fourth Quarter and Fiscal Year 2025 Financial Results

LIFE

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 20, 2026, 4:01 PM EST - 2 months ago

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

Feb 18, 2026, 8:00 AM EST - 2 months ago

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

Ethos to Announce Fourth Quarter 2025 Financial Results on February 25, 2026

Feb 5, 2026, 4:05 PM EST - 2 months ago

Ethos to Announce Fourth Quarter 2025 Financial Results on February 25, 2026

LIFE

The IPO Market Faces a Busy Week. These Stocks Are Making Their Debuts.

Feb 3, 2026, 2:46 PM EST - 2 months ago

The IPO Market Faces a Busy Week. These Stocks Are Making Their Debuts.

FPS LFTO YSS

aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis

Feb 3, 2026, 8:00 AM EST - 2 months ago

aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis

Insurance platform Ethos Technologies valued at $1.2 billion in Nasdaq debut

Jan 29, 2026, 12:30 PM EST - 3 months ago

Insurance platform Ethos Technologies valued at $1.2 billion in Nasdaq debut

Ethos Announces Pricing of Initial Public Offering

Jan 28, 2026, 10:38 PM EST - 3 months ago

Ethos Announces Pricing of Initial Public Offering

Ethos Technologies prices US IPO at $19/share, Bloomberg News reports

Jan 28, 2026, 9:05 PM EST - 3 months ago

Ethos Technologies prices US IPO at $19/share, Bloomberg News reports

Ethos and North American Collaborate to Offer Accumulation Indexed Universal Life Product

Jan 7, 2026, 8:01 AM EST - 3 months ago

Ethos and North American Collaborate to Offer Accumulation Indexed Universal Life Product

Ethos and Aflac Partner to Bring Supplemental Health Product Suite to Independent Distribution

Dec 18, 2025, 8:01 AM EST - 4 months ago

Ethos and Aflac Partner to Bring Supplemental Health Product Suite to Independent Distribution

Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders

Dec 15, 2025, 2:45 PM EST - 4 months ago

Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders

aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR

Dec 8, 2025, 3:25 AM EST - 4 months ago

aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR

ATYR DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Dec 7, 2025, 9:02 AM EST - 4 months ago

ATYR DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure

Dec 6, 2025, 12:58 PM EST - 4 months ago

ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Dec 4, 2025, 10:56 AM EST - 5 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Lawsuit – ATYR

Dec 3, 2025, 4:21 PM EST - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Lawsuit – ATYR

ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Dec 3, 2025, 9:22 AM EST - 5 months ago

ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Dec 1, 2025, 6:32 PM EST - 5 months ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

The Short List — Top 10 Most Shorted Stocks Right Now

Nov 26, 2025, 11:34 AM EST - 5 months ago

The Short List — Top 10 Most Shorted Stocks Right Now

HIMS HTZ LCID NTLA REPL SOC WEN

aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman

Nov 25, 2025, 4:08 PM EST - 5 months ago

aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Pharma, Inc. Lawsuit - ATYR

Nov 20, 2025, 8:45 AM EST - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Pharma, Inc. Lawsuit - ATYR

ATYR INVESTOR NOTICE: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman

Nov 18, 2025, 2:03 PM EST - 5 months ago

ATYR INVESTOR NOTICE: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman

aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities Lawsuit; Class Period Significantly Enlarged -- Hagens Berman

Nov 11, 2025, 9:23 AM EST - 5 months ago

aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities Lawsuit; Class Period Significantly Enlarged -- Hagens Berman

aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 10, 2025, 8:00 AM EST - 5 months ago

aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference

aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update

Nov 6, 2025, 4:01 PM EST - 6 months ago

aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update

ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ATyr Pharma

Nov 4, 2025, 11:49 AM EST - 6 months ago

ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ATyr Pharma

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Oct 30, 2025, 11:33 AM EDT - 6 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

trader2sde
trader2sde Apr. 25 at 10:19 AM
$ATYR reminder.... imho no coincidence and it is about time. he is a trouble maker! . Dr. Vinay Prasad, the FDA's controversial head of vaccine and biotech evaluation (CBER), will leave his post at the end of April 2026, marking his second departure from the role in less than a year. His tenure was marked by friction with the biotech industry and intense scrutiny over regulatory decisions regarding drug approvals. Key Details on the Departure: Second Departure: Prasad previously resigned in July 2025, returning only two weeks later before this final, planned exit. Controversial Tenure: He was known for pushing stricter review standards and challenging industry practices, such as questioning gene therapies and delaying certain approvals. Industry Clashes: His recent actions involved disputes with companies like UniQure (over Huntington's disease trials) and Moderna (regarding an mRNA flu vaccine).
0 · Reply
jamersonmoody
jamersonmoody Apr. 24 at 7:32 PM
$ATYR lol fuck this pos
0 · Reply
Bocholter
Bocholter Apr. 24 at 7:02 PM
$ATYR lovely shorties…..think about it🔥🔥🔥🤑🤑🤑😊😊😊
0 · Reply
Spiceman63
Spiceman63 Apr. 24 at 6:02 PM
$ATYR It should be any day… “We look forward to meeting with the FDA in mid-April to review the results of our Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr Pharma. “We expect to provide an update regarding the outcome of the meeting following the receipt of the official meeting minutes.”
2 · Reply
Bocholter
Bocholter Apr. 24 at 4:18 PM
$ATYR buy buy buy guys🤑🔥🔥🔥
0 · Reply
Bocholter
Bocholter Apr. 24 at 3:01 PM
$ATYR The short sellers are about to break a sweat. The good news… we’re finally heading north again. Keep an eye on the chart today 🔥🔥🔥🤑🤑🤑
0 · Reply
trader2sde
trader2sde Apr. 24 at 10:42 AM
$ATYR
0 · Reply
trader2sde
trader2sde Apr. 24 at 10:42 AM
$ATYR
0 · Reply
ClearCities
ClearCities Apr. 23 at 9:38 PM
$ATYR all the focus is on meeting for type c i expect a 2sp +and stabilize
1 · Reply
Houzehero
Houzehero Apr. 23 at 8:54 PM
$ATYR Forget today's noise, FDA minutes are due to drop by Mid-May and call options are leaning toward ⬆️
1 · Reply
trader2sde
trader2sde Apr. 23 at 4:28 PM
$ATYR most stocks today down. nothing to do with ATYR. same daily chart pattern.
1 · Reply
antant
antant Apr. 23 at 10:53 AM
$ATYR any update from recent meeting with FDA?
1 · Reply
trader2sde
trader2sde Apr. 22 at 4:08 PM
$ATYR PULMONARY SARCOIDOSIS kills more than thought.. FDA is on watch... "People with pulmonary sarcoidosis who are older at diagnosis or have more severe lung damage may face a higher risk of death."
1 · Reply
trader2sde
trader2sde Apr. 22 at 4:04 PM
$ATYR
0 · Reply
investodayyyy
investodayyyy Apr. 21 at 3:41 PM
$ATYR will this ever go higher than 1$?
1 · Reply
Unknown_Stuntman
Unknown_Stuntman Apr. 21 at 2:08 PM
$ATYR surprised this turd hasnt gone to 0.30 and RS w/ dillution.
2 · Reply
doangroup789
doangroup789 Apr. 20 at 8:16 PM
$ATYR When chedule meeting happen.thank
0 · Reply
trader2sde
trader2sde Apr. 20 at 6:13 PM
$ATYR reminder...
0 · Reply
trader2sde
trader2sde Apr. 20 at 6:01 PM
$ATYR lung sarcoidosis is a killer (new Spain study). FDA better be careful in the meeting and stop their bs ( or biasing with bigger pharmas) https://sarcoidosisnews.com/news/age-lung-damage-predict-death-risk-pulmonary-sarcoidosis-large-study/
0 · Reply
dewmoore
dewmoore Apr. 20 at 11:50 AM
$ATYR is proving it's NOT a one-trick pony. They are currently at #AACR26 in San Diego showcasing their NRP2 platform. (tomorrow) Presentation Details: AACR Annual Meeting 2026 San Diego Convention Center, San Diego Tuesday, April 21, 2026. 9:00 AM – 12:00 PM PT $ATYR is proving that their neuropilin-2 (NRP2) research isn't just a side project—it’s a true platform. While efzofitimod is the lead, aTyr is advancing ATYR0101 with a focus on lung fibrosis and oncology (projected to reach nearly $50 Billion by 2030) ...The "platform" potential here is massive. Everyone is watching the FDA. We should hear back from the mid-April Type C meeting in just a few weeks. Recent FDA changes gives us a real path forward, especially since patients are still on the drug in the real world right now. Institutions still rocking with us at 55%. Even after the drop from $6 to $1, the smart money is still here. I really like our chances for a major comeback! GLTA 🚀
3 · Reply
trader2sde
trader2sde Apr. 19 at 5:34 PM
$ATYR
0 · Reply
RocketLabs
RocketLabs Apr. 17 at 4:24 PM
$ATYR We have some new institutional holders who didn't hold before. No huge positions, but nice to see.
2 · Reply